AbbVie trims annual profit forecast after expected $2.7 billion R&D hit

(Reuters) -Drugmaker AbbVie said on Friday it has lowered its annual profit forecast, after a flagging an expected $2.7 billion charge related to in-process research and development (IPR&D) expenses in the third quarter. Shares of the North Chicago-based company were down nearly 1% at $232.0 in extended trade. AbbVie said in a regulatory filing that such expenses may arise from collaborations, licensing deals or asset buys, but are not forecast due to uncertainty around timing and occurrence. It did not ...